Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009;11(3):229. https://doi.org/10.1186/ar2669.

Article  PubMed  PubMed Central  Google Scholar 

Sikes D, Crump G, Thomas K, et al. Population management of rheumatoid arthritis (RA) in rheumatology practices: A quality improvement project. Arthritis Rheumatol: Abstract Supplement. 2014;66(11):S596.

Google Scholar 

Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update [published correction appears in ann rheum Dis. 2023;82(3):e76. Doi: 10.1136/ard-2022-223356corr1]. Ann Rheum Dis. 2023;82(1):3–18. https://doi.org/10.1136/ard-2022-2233.

Article  PubMed  CAS  Google Scholar 

Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924–39. https://doi.org/10.1002/acr.24596.

Article  PubMed  PubMed Central  Google Scholar 

Di Matteo A, Bathon JM, Emery P. Rheumatoid arthritis. Lancet. 2023;402(10416):2019–33. https://doi.org/10.1016/S0140-6736(23)01525-8.

Article  PubMed  Google Scholar 

Kearsley-Fleet L, Davies R, De Cock D, et al. Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2018;77(10):1405–12. https://doi.org/10.1136/annrheumdis-2018-213378.

Article  PubMed  PubMed Central  Google Scholar 

Bécède M, Alasti F, Gessl I, et al. Risk profiling for a refractory course of rheumatoid arthritis. Semin Arthritis Rheum. 2019;49(2):211–7. https://doi.org/10.1016/j.semarthrit.2019.02.004.

Article  PubMed  Google Scholar 

de Hair MJH, Jacobs JWG, Schoneveld JLM, van Laar JM. Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need. Rheumatology (Oxford). 2018;57(7):1135–44.

PubMed  Google Scholar 

Baker KF, Spierings J, Brom M, et al. Cure as a treatment target in rheumatoid arthritis and systemic sclerosis-achievable aim or mission impossible? FOREUM stimulates new industry-academia collaboration. Ann Rheum Dis. 2025;84(2):153–7. https://doi.org/10.1136/ard-2024-226772.

Article  PubMed  CAS  Google Scholar 

Reddy V, Klein C, Isenberg DA, et al. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatology (Oxford). 2017;56(7):1227–37. https://doi.org/10.1093/rheumatology/kex067.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yin Yi, et al. Can we cure rheumatoid arthritis? Curr Opin Immunol. 2025;94:102561. https://doi.org/10.1016/j.coi.2025.102561.

Article  PubMed  CAS  Google Scholar 

Alivernini S, Firestein GS, McInnes IB. The pathogenesis of rheumatoid arthritis. Immunity. 2022;55(12):2255–70. https://doi.org/10.1016/j.immuni.2022.11.009.

Article  PubMed  CAS  Google Scholar 

Gravallese EM, Firestein GS. Rheumatoid arthritis - common origins, divergent mechanisms. N Engl J Med. 2023;388(6):529–42. https://doi.org/10.1056/NEJMra2103726.

Article  PubMed  CAS  Google Scholar 

Weyand CM, Goronzy JJ. Immune aging in rheumatoid arthritis. Arthritis Rheumatol. 2025. https://doi.org/10.1002/art.43105.

Article  PubMed  PubMed Central  Google Scholar 

Lliso-Ribera G, Humby F, Lewis M, et al. Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC). Ann Rheum Dis. 2019;78(12):1642–52. https://doi.org/10.1136/annrheumdis-2019-215751.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhang F, Jonsson AH, Nathan A, et al. Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes. Nature. 2023;623(7987):616–24. https://doi.org/10.1038/s41586-023-06708-y.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rivellese Felice, et al. Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials. The Lancet Rheumatology. 2023;5(11):e648–59. https://doi.org/10.1016/S2665-9913(23)00241-2.

Article  PubMed  CAS  Google Scholar 

Murillo-Saich JD, Diaz-Torne C, Ortiz MA, et al. Metabolomics profiling predicts outcome of tocilizumab in rheumatoid arthritis: an exploratory study. Metabolomics. 2021;17(9):74. https://doi.org/10.1007/s11306-021-01822-2.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Han Peng, et al. Overview of mechanisms and novel therapies on rheumatoid arthritis from a cellular perspective. Front Immunol. 2024;15:1461756. https://doi.org/10.3389/fimmu.2024.1461756.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Genovese MC, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha Inhibition. New Engl J Med Vol. 2005;353:1114–23. https://doi.org/10.1056/NEJMoa050524.

Article  CAS  Google Scholar 

Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18(3):153–67. https://doi.org/10.1038/nri.2017.108.

Article  PubMed  CAS  Google Scholar 

Yao S, Chen L. PD-1 as an immune modulatory receptor. Cancer J. 2014;20(4):262–4. https://doi.org/10.1097/PPO.0000000000000060.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Feng Y, Deyanat-Yazdi G, Newburn K, et al. <article-title update="added">PD-1 antibody interactions with Fc gamma receptors enable PD-1 agonism to inhibit T cell activation – therapeutic implications for autoimmunity. J Autoimmun. 2024;149:103339. https://doi.org/10.1016/j.jaut.2024.103339.

Article  PubMed  CAS  Google Scholar 

Reynolds G. Rheumatic complications of checkpoint inhibitors: lessons from autoimmunity. Immunol Rev. 2023;318(1):51–60. https://doi.org/10.1111/imr.13242.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tuttle J, Drescher E, Simón-Campos JA, et al. A phase 2 trial of Peresolimab for adults with rheumatoid arthritis. N Engl J Med. 2023;388(20):1853–62. https://doi.org/10.1056/NEJMoa2209856.

Article  PubMed  CAS  Google Scholar 

Anaptys announces rosnilimab. Achieved positive results in RA phase 2b trial and highest ever reported CDAI LDA response over 6 months [news release]. AnaptysBio Inc.; 2025; 12.

Ling ITC, Marciniak SJ, Clarke SH, et al. Safety, tolerability, and efficacy of the PD-1 agonist antibody JNJ-67484703 in adults with active rheumatoid arthritis: results of a multicenter, double-blind, placebo-controlled, randomized, multiple-dose phase Ib study. Ther Adv Musculoskelet Dis. 2025. https://doi.org/10.1177/1759720X251385857.

Article  PubMed  PubMed Central  Google Scholar 

Nepal D, Putman M. Phase 2 trial of Peresolimab for adults with rheumatoid arthritis. N Engl J Med. 2023;389(4):378–9. https://doi.org/10.1056/NEJMc2307020.

Article  PubMed  Google Scholar 

Guo Y, Walsh AM, Fearon U, Smith MD, Wechalekar MD, Yin X, et al. CD40L-dependent pathway is active at various stages of rheumatoid arthritis disease progression. J Immunol. 2017;198(11):4490–501. https://doi.org/10.4049/jimmunol.1601988.

Article  PubMed  CAS  Google Scholar